Jam

JOYY Inc. (NASDAQ: JOYY) reported mixed Q1 2025 results, with lower overall revenue but improved profitability driven by diversification and cost management. Non-livestreaming revenue surged. The company returned capital to shareholders via dividends and share repurchases. User metrics showed declines, but net cash remains strong. JOYY forecasts revenue growth for Q2, emphasizing its strategic shift and diversified business model, particularly in advertising.

Silvercorp Metals Inc. (TSX: SVM; NYSE American: SVM) declared a semi-annual cash dividend of US$0.0125 per common share, payable by June 26, 2025, to shareholders of record as of June 6. The Canadian precious metals producer highlighted the dividend’s eligibility for favorable tax treatment under Canadian regulations, reflecting confidence in its operational stability amid volatile silver prices (US$28–34/oz this quarter). With 14 consecutive years of positive cash flow, Silvercorp has distributed over US$145 million to shareholders since 2011 through dividends and buybacks. The company’s shares rose 18% YTD, outperforming peers, while its strategy emphasizes low-cost mining, exploration, strategic acquisitions, and ESG integration across global operations.

Alvotech (NASDAQ: ALVO) will hold its 2025 Annual General Meeting on June 25 in Reykjavik, with virtual access available. Shareholders will review governance updates, financial results, and strategies to bolster its position in the biosimilars market, projected to yield $50 billion in global savings by 2027. Key discussions include expanding its biosimilar pipeline, regulatory progress in the U.S. and Europe, and addressing pricing challenges and patent cliffs. Analysts highlight priorities like commercial partnerships, scalable manufacturing, and differentiation in immunology and oncology. The meeting may signal strategic shifts as Alvotech navigates evolving FDA regulations and leverages biosimilars to counter pharmaceutical revenue declines, emphasizing speed-to-market and cost efficiency.

HyOrc Corporation (OTC: ASPZ) is expanding globally with hydrogen rail systems, green methanol production, and modular off-grid energy solutions. Its hybrid technology merges hydrogen combustion with organic Rankine cycle turbines, offering diesel alternatives at cost parity without subsidies. Key strengths include a diversified project pipeline, focus on decarbonization markets (EU/UK), and planned OTCQB uplisting. Challenges encompass scaling risks, unproven technical differentiation, and undisclosed partnership details. Analysts highlight potential supply chain disruption through containerized systems, while HyOrc targets rail operators and industries needing emissions-compliant solutions. The company emphasizes an asset-light, licensing-based model amid tightening global emissions regulations.

Y-mAbs Therapeutics presented Phase 1 Trial 1001 data for its GD2-SADA PRIT therapy at the Neuroblastoma Research Meeting, targeting recurrent/refractory GD2-positive solid tumors (neuroblastoma, lung cancer, sarcoma, melanoma). The two-step approach combines non-radioactive GD2-SADA proteins with Lutetium-177 to selectively irradiate tumors. Following Part A dose optimization, preliminary safety/efficacy results will be disclosed May 28th. If proven effective, this precision radiotherapy platform could address high-unmet needs across oncology markets, positioning YMAB for potential partnerships in the $6.8B radiopharma sector.

Atico Mining secured a 30-year concession for Colombia’s El Roble copper-gold mine, stabilizing operations until 2055 and releasing $10M worth of pledged copper concentrate for immediate liquidity. The deal resolves a $12M arbitration liability, with $3M paid and $10.7M deferred to 2025–2026, aligned with projected cash flows. It transitions regulatory terms to modern mining codes but adds community development and state compensation costs. CEO Ganoza emphasized the concession’s role in shifting focus to growth and exploration. Risks include copper price volatility and inflation-adjusted settlement increases. The mine remains central to Atico’s revenue amid Colombia’s evolving mining policies.

COSCIENS Biopharma faces activist pressure as investors Goodwood Fund and Puccetti Funds Management nominate six board directors, signaling a push for strategic changes. The firm, known for plant-based innovations in skincare (e.g., Aveeno’s oat compounds) and diagnostics like macimorelin, is evaluating the proposal amid scrutiny over its clinical trial pace, particularly for its cholesterol drug candidate. Balancing cosmeceutical growth with pharmaceutical ambitions, COSCIENS confronts investor demands for accelerated commercialization and governance reforms. Challenges include trial uncertainties for its growth hormone diagnostic and market pressures, with leadership decisions likely to shape its trajectory in competitive biopharma markets.

Axcap Ventures (CSE: AXCP) acquired Carlyle Commodities’ Newton Gold Project in British Columbia for up to $8 million, gaining full ownership of the 23,003-hectare property with an inferred resource of 843,000 oz gold and 4.5 million oz silver. The deal includes $500,000 cash, 3.75 million shares, and warrants for Carlyle, plus performance-based incentives tied to resource expansion and feasibility milestones. A 2% net smelter royalty includes an option for Axcap to buy back half for $2 million. The acquisition positions Axcap to explore the underexplored Cariboo region amid high gold prices, though challenges include low 0.64 g/t grades and potential shareholder dilution. Initial drilling results are expected in late 2025.

TotalEnergies launched oil production from its Mero-4 phase in Brazil’s pre-salt Santos Basin, bolstering its low-carbon strategy. The offshore project, linked to the 180,000 b/d Alexandre de Gusmão FPSO, employs emissions-reduction technologies like gas reinjection. Combined with existing units, Mero’s total output reaches 770,000 b/d. TotalEnergies’ stake is expected to deliver 100,000 boe/d. Operated by the Libra Consortium (Petrobras, TotalEnergies, Shell, CNPC, CNOOC, and Pré-Sal Petróleo), the project aligns with the company’s 3% annual production growth target by 2030. TotalEnergies also emphasized Brazil’s role in its renewables expansion, including a 12 GW solar/wind joint venture, balancing hydrocarbon growth with sustainability goals.

Innovent Biologics’ dual GCG/GLP-1 agonist mazdutide demonstrated significant weight loss (14.84% vs. 0.47% placebo) in a Phase 3 trial (GLORY-1) with 610 Chinese adults with obesity over 48 weeks, published in *NEJM*. Over 50% achieved ≥15% weight reduction, alongside improved cardiovascular and liver health. Safety aligned with GLP-1 therapies, with transient gastrointestinal effects. This marks the first NEJM-published metabolic therapy trial from China, signaling the nation’s rise in drug innovation. Experts emphasized mazdutide’s potential in addressing China’s obesity crisis under “Healthy China 2030.” Partnerships with Eli Lilly and ongoing trials aim to expand its use in metabolic diseases.